Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Emtricitabine and Descovy in Patients With Mild Cognitive Impairment
NCT07210528Phase 1Active, not recruiting
- Sponsor
- National University Hospital
- Start
- Jun 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of emtricitabine and tenofovir alafenamide in Mild Cognitive Impairment (MCI) (4 arms), sponsored by National University Hospital. Primary endpoint: Number of participants with treatment-related Adverse/Serious Adverse Events at 12 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
emtricitabinetenofovir alafenamide
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT07210528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07210528.